Literature DB >> 32535684

The tissue expression pattern of CA 19.9 is associated with oncological features in medullary thyroid carcinoma.

Carla Vaz Ferreira Vargas1, Lucieli Ceolin1, Rafael Selbach Scheffel1,2, Antônio Felippe Benini1, Márcia Silveira Graudenz1,3, Ana Luiza Maia4.   

Abstract

PURPOSE: Elevated serum levels of carbohydrate antigen 19.9 (CA19.9), a well-established tumor marker in pancreatic neoplasms, has been proposed as a prognostic marker of tumor aggressiveness in medullary thyroid carcinoma (MTC). A hypothesis of C-cell dedifferentiation has been raised. Here, we evaluated the expression of CA19.9 and CD133, a stem cell marker, in MTC tissues.
METHODS: MTC samples from patients attending a university-based hospital were evaluated for CA19.9 and CD133 expression by immunohistochemistry. Clinical data were retrieved from medical records.
RESULTS: Tumor specimens from 70 MTC patients (57.1% hereditary) were evaluated. The age at diagnosis was 36.1 ± 16.3 years, and 58.6% were female; 53% of patients had cervical and 20% distant metastases. CA19.9 staining was detected in 87% of the samples, but no association was observed with biochemical markers, tumor size, local or distant metastases (All P > 0.05). Remarkable, CA19.9 expression was higher in the metastasis than in primary tumor samples (P = 0.0002). CD133 was expressed in 90.5% samples, but no correlation was found with CA19.9. Interestingly, we identified three distinct expression patterns to CA19.9: individual, focal, and diffuse cells. Sporadic MTC was associated with the individual cell pattern (70.6%), while the hereditary form with the focal expression pattern (63.9%; P = 0.04). Remarkably, the diffuse pattern was associated with larger tumor size and distant metastases (P = 0.032).
CONCLUSIONS: The majority of samples stained for CA19.9, suggesting it is an MTC cell-intrinsic feature. Three distinct expression patterns were identified, which were associated with the hereditary or sporadic form, larger tumor size, and presence of metastases.

Entities:  

Keywords:  C-cell dedifferentiation; CA 19.9; CD133; Medullary thyroid carcinoma

Mesh:

Substances:

Year:  2020        PMID: 32535684     DOI: 10.1007/s12020-020-02377-3

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  16 in total

1.  Metastatic medullary thyroid cancer presenting with elevated levels of CA 19-9 and CA 125.

Authors:  Sofiya Milman; Kathleen D Whitney; Norman Fleischer
Journal:  Thyroid       Date:  2011-07-13       Impact factor: 6.568

2.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

Review 3.  Advances and controversies in the management of medullary thyroid carcinoma.

Authors:  Ana Luiza Maia; Simone Magagnin Wajner; Carla Vaz Ferreira Vargas
Journal:  Curr Opin Oncol       Date:  2017-01       Impact factor: 3.645

4.  Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.

Authors:  Jacques Barbet; Loïc Campion; Françoise Kraeber-Bodéré; Jean-François Chatal
Journal:  J Clin Endocrinol Metab       Date:  2005-08-09       Impact factor: 5.958

5.  Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients.

Authors:  M R Pelizzo; I M Boschin; P Bernante; A Toniato; A Piotto; C Pagetta; O Nibale; L Rampin; P C Muzzio; D Rubello
Journal:  Eur J Surg Oncol       Date:  2006-11-27       Impact factor: 4.424

6.  The pitfalls of CA19-9: routine testing and comparison of two automated immunoassays in a reference oncology center.

Authors:  Rita Passerini; Maria C Cassatella; Sara Boveri; Michela Salvatici; Davide Radice; Laura Zorzino; Claudio Galli; Maria T Sandri
Journal:  Am J Clin Pathol       Date:  2012-08       Impact factor: 2.493

7.  Medullary thyroid cancer secreting carbohydrate antigen 19-9 (Ca 19-9): a fatal case report.

Authors:  Rossella Elisei; Loredana Lorusso; Cristina Romei; Valeria Bottici; Salvatore Mazzeo; Claudio Giani; Emilio Fiore; Liborio Torregrossa; Andrea Cacciato Insilla; Fulvio Basolo; Antonello Guerini; Alessandra Menghi; Alessandro Poletti; Luisa Cugudda; Paolo Vitti
Journal:  J Clin Endocrinol Metab       Date:  2013-07-16       Impact factor: 5.958

8.  Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times.

Authors:  Anne Laure Giraudet; Abir Al Ghulzan; Anne Aupérin; Sophie Leboulleux; Ahmed Chehboun; Frédéric Troalen; Clarisse Dromain; Jean Lumbroso; Eric Baudin; Martin Schlumberger
Journal:  Eur J Endocrinol       Date:  2008-02       Impact factor: 6.664

9.  CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.

Authors:  Viviane Hess; Bengt Glimelius; Philipp Grawe; Daniel Dietrich; György Bodoky; Thomas Ruhstaller; Emilio Bajetta; Piercarlo Saletti; Arie Figer; Werner Scheithauer; Richard Herrmann
Journal:  Lancet Oncol       Date:  2008-02       Impact factor: 41.316

10.  CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials.

Authors:  N R Maisey; A R Norman; A Hill; A Massey; J Oates; D Cunningham
Journal:  Br J Cancer       Date:  2005-10-03       Impact factor: 7.640

View more
  1 in total

Review 1.  Carbohydrate antigen 19-9 - tumor marker: Past, present, and future.

Authors:  Tsinrong Lee; Thomas Zheng Jie Teng; Vishal G Shelat
Journal:  World J Gastrointest Surg       Date:  2020-12-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.